$LRMR News

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

Here’s What Citi Thinks About Larimar Therapeutics (LRMR)

LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns

HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia - Slideshow

Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)

Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript

Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know

Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug

Larimar Therapeutics Submits First Module Of Rolling BLA Submission To FDA For Accelerated Approval Of Nomlabofusp; Remaining Modules Expected To Be Submitted In H2 2026